Date Title Description PDF
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
08 Nov 2023 On P&L The Company releases the press release related to the first nine months of 2023 financial results Download
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download

Pages

Date Title Description PDF
11 Aug 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 August and 10 August 2023 Download
03 Aug 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 26 July 2023 and 2 August 2023 Download
28 Jul 2023 On business and financial situation ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® Download
05 Jul 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2023 Download
26 Jun 2023 Other relevant information The Company informs about the dividends payment Download

Pages

Date Title Description PDF
10 May 2018 Otros sobre negocio y situación financiera Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) Download
25 Apr 2018 Información sobre resultados ROVI releases the press release related to the 2018 first quarter financial results Download
25 Apr 2018 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting Download
25 Apr 2018 Información sobre resultados ROVI releases the 2018 first quarter results presentation Download
04 Apr 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2018 Download

Pages